CEL-SCI Corp

CVM

Market cap $24.1M

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.